Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.59 |
| ▸ | CPT2 | P23786 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | HMGCR | P04035 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | BHMT | Q93088 | 3/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12808778 | 0.97 | KDM4E (0.56) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL433760 | 0.88 | KDM4E (0.54) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL14314268 | 0.87 | KDM4E (0.74) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL22561607 | 0.87 | KDM4E (0.54) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL11982038 | 0.87 | KDM4E (0.48) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL14272837 | 0.87 | KDM4E (0.48) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL13882708 | 0.87 | KDM4E (0.48) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL30854909 | 0.87 | KDM4E (0.65) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL48109 | 0.87 | KDM4E (0.65) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL17187568 | 0.86 | KDM4E (0.52) | KDM4EFFAR1CPT2TDP1HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10322187-B2 | Reduced toxicity molecular conjugates of anti-fungal agents | LEHIGH UNIVERSITY | 2019-06-18 | — | — | US | disclosed |
| EP-2952516-B1 | POLYSILOXANE COMPOUND AND DENTAL MATERIALS THAT CAN BE PRODUCED FROM SAME | VOCO GMBH (DE) | 2017-08-09 | — | — | EP | disclosed |
| US-20170042923-A1 | REDUCED TOXICITY MOLECULAR CONJUGATES OF ANTI-FUNGAL AGENTS | LEHIGH UNIVERSITY | 2017-02-16 | — | — | US | disclosed |
| EP-2952516-A1 | POLYSILOXANE COMPOUND AND DENTAL MATERIALS THAT CAN BE PRODUCED FROM SAME | VOCO GmbH (DE) | 2015-12-09 | — | — | EP | disclosed |
| US-20150342841-A1 | POLYSILOXANE COMPOUND AND DENTAL MATERIALS THAT CAN BE PREPARED FROM IT | VOCO GMBH (DE) | 2015-12-03 | — | — | US | disclosed |
| US-20140242795-A1 | Volatile Imidazoles and Group 2 Imidazole Based Metal Precursors | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2371821-B1 | Volatile imidazoles and group 2 imidazole based metal precursors | AIR PROD & CHEM (US) | 2014-06-18 | — | — | EP | disclosed |
| US-8703103-B2 | Volatile imidazoles and group 2 imidazole based metal precursors | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120035351-A1 | Volatile Imidazoles and Group 2 Imidazole Based Metal Precursors | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| EP-2371821-A1 | Volatile imidazoles and group 2 imidazole based metal precursors | Air Products and Chemicals, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20100113599-A1 | AMPHIPATHIC CARBOXYLATES FOR THE TREATMENT OF IMMUNE-RELATED DISORDERS | SYNDROMEX LTD. C/O YISSUM RESEARCH DEVELOPMENT COMPANY, OF (IL) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113599-A1 | AMPHIPATHIC CARBOXYLATES FOR THE TREATMENT OF IMMUNE-RELATED DISORDERS | MALT1, TLR9, TLR6 | KDM4E 2087/4885FFAR1 157/4885CPT2 134/4885 |
| US-10322187-B2 | Reduced toxicity molecular conjugates of anti-fungal agents | ANTXR2, FABP7, ERG28 | KDM4E 4221/4885FFAR1 2549/4885CPT2 1842/4885 |
| US-20120035351-A1 | Volatile Imidazoles and Group 2 Imidazole Based Metal Precursors | CACNG5, BST2, API5 | KDM4E 1388/4885FFAR1 4059/4885CPT2 4668/4885 |
| US-20150342841-A1 | POLYSILOXANE COMPOUND AND DENTAL MATERIALS THAT CAN BE PREPARED FROM IT | SMCHD1, IPO5, IPO9 | KDM4E 548/4885FFAR1 3947/4885CPT2 4786/4885 |
| US-20170042923-A1 | REDUCED TOXICITY MOLECULAR CONJUGATES OF ANTI-FUNGAL AGENTS | ANTXR2, FABP7, ERG28 | KDM4E 4221/4885FFAR1 2549/4885CPT2 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.